Raj Jadeja also known as Rajdeepsinh I Jadeja (RDJ) is a Rajkot based entrepreneur who owns multiple businesses namely Shree Khodiyar Transport, which was established in 1984 which is the biggest transport company in Saurashtra region in Gujarat having 16 branch offices headquarters being Bhavnagar and Rajkot. The finance and accounts aspect of the business is completely looked after by Raj Jadeja.

His other firm, Eleven Industries is a newly established firm by Rdj in 2019 which is a mining company in the Kutch region in Gujarat. The entire company is completely looked at by Rdj. The main aim being the export market.

Other than businesses, Raj Jadeja is also fond of travel, lifestyle and has also been a model for the UK models company in London during his time there when he was a student at Brunel University, London for 3 years. Having visited over 9 countries at a very young age of 23 due to Business meetings and Studies, Rdj is also a lifestyle influencer which can also be seen on his Instagram. Additionally, while being an Entrepreneur, Model, and lifestyle Influencer, Raj is also a professional photographer who is fond of clicking the life around him and himself.

Instagram – https://www.instagram.com/rdjworld_/

Rdj is also involved in several charitable trusts for Donations in London which helps providing shelter to the poor families in winter. Also, in India an initiative by Sadguru named Rally for rivers which utilize its donations in planting trees countrywide. 

Maluma happened to make a stop in Dubai before finishing his 2020 world tour. While in Dubai Maluma had the opportunity to conduct a photo-shoot for GQ Middle East’s March cover. Of course, every photo shoot has a list of names when it comes to essential for stylist, makeup, set designer, and hairstylist. When it came down to selecting the hairstylist of course Khalfan Yasin’s shop MK Barbershop was the only one to consider to ensure Maluma had the correct look to represent himself and the highly fashionable middle east culture. 

Yasin a global concierge, lifestyle specialist, and entrepreneur continues to master the UAE scene effortlessly and ensuring his business and brands always stay relevant to today’s times. No task or connection that needs to be made is to difficult for Khalfan; as he continues to show the world what the “ #AKLifeStyle” is all about.

But there is still an opportunity to substantially reduce the death toll by prioritising the most critical services, specifically antiretroviral therapy for HIV, timely TB diagnosis and treatment, and provision of long-lasting insecticide-treated nets for malaria, researchers say.

Some low- and middle-income countries (LMICs) could see HIV, tuberculosis (TB), and malaria deaths increase by as much as 10%, 20%, and 36% respectively over the next 5 years due to the disruption of health services caused by the COVID-19 pandemic and its response, according new modelling research published in The Lancet Global Health journal.

Modelling the public health impact of COVID-19 on HIV, TB, and malaria in LMICs over the next 5 years, researchers estimate that in areas heavily affected by these major infectious diseases, the impact of COVID-19 disruption on years of life lost (the number of years a person would have been expected to live had they not died of a particular cause) could, in the worst case, be of a similar scale to the direct impact of the pandemic itself.

The COVID-19 pandemic has the potential to cause substantial disruptions by overwhelming already fragile health systems, or through response measures limiting routine programme activities and care-seeking, and interrupting medical supply chains. But maintaining core services for HIV, TB, and malaria—specifically access to antiretroviral therapy (ART), timely TB diagnosis and treatment, and early resumption of the distribution of long-lasting insecticide-treated nets (LLINs) and antimalarial treatment—could largely mitigate the broader health impact of the COVID-19 pandemic, researchers say.

However, the authors caution that predicting the true impact of the ongoing COVID-19 pandemic and its response on other diseases is fraught with difficulty, especially when so much remains unknown about the virus and the extent to which other disease programmes may be disrupted, and how this might impact population health. They flag that their study aims to quantify the potential scale of the impact of COVID-19, and to guide how it could be minimised, rather than provide precise estimates.

Malaria deaths worldwide have reduced by half since 2000, but progress has stalled as mosquitoes and parasites gain resistance to treatment. Around 94% of deaths occur in sub-Saharan Africa where malaria claimed an estimated 380,000 lives in 2018. Similarly, global HIV/AIDS deaths have halved in a decade driven by the availability of ART. In 2019, around 690,000 people died from the disease worldwide, the vast majority in LMICs. An estimated 49 million lives were saved through TB diagnosis and treatment between 2000 and 2015, but the disease still claimed the lives of 1.8 million people in 2018—with over 95% of these deaths occurring in LMICs [2].

“The COVID-19 pandemic and actions taken in response to it could undo the some of the advances made against major diseases such as HIV, TB, and malaria over the past two decades, compounding the burden caused by the pandemic directly”, says Professor Timothy Hallett from Imperial College London, UK, who co-led the research. “In countries with a high malaria burden and large HIV and TB epidemics, even short-term disruptions could have devastating consequences for the millions of people who depend on programmes to control and treat these diseases. However, the knock-on impact of the pandemic could be largely avoided by maintaining core services and continuing preventative measures.” [1]

He continues, “Our findings underscore the extraordinarily difficult decisions facing policy makers. Well managed, long-term suppression measures could avert the most COVID-19 deaths. But if these interventions are not well managed, they could cause people to stay away from hospitals and clinics and force public health programmes to be cancelled, leading to a large spike in deaths from other major infectious diseases that had been coming under control.” [1]

Discussing the implications of the findings in a linked Comment, Peter Sands, Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland (who was not involved in the study) says, “The knock-on impact on HIV, tuberculosis, and malaria could potentially be even worse than this study suggests, and in some countries, it could be even worse than the direct impact of COVID-19. The Global Fund conducts a biweekly qualitative survey across the more than 100 countries in which it invests; the latest published results suggest that 85% of HIV, 78% of tuberculosis, and 73% of malaria programmes are being disrupted. 18% of HIV programmes, 17% of tuberculosis programmes, and 19% of malaria programmes are experiencing high or very high disruption.”

He adds, “In countries heavily affected by HIV, tuberculosis, and malaria, COVID-19 could result in many years of hard-won gains being reversed. We cannot let this happen. We need more resources and decisive action, and we must measure success not just in terms of minimising the direct impact of COVID-19, but in terms of minimising its total impact, including the knock-on impact on HIV, tuberculosis, and malaria.”

In this study, the researchers assumed a basic reproductive number (R0; the average number of people each individual with the virus is likely to infect) of 3 to develop four different policy response scenarios to the COVID-19 pandemic—no action, mitigation (which represents a 45% reduction in R0 for 6 months using interventions such as physical distancing), suppression-lift (a 75% reduction in R0 for 2 months), or suppression a 75% reduction in R0 for 1 year; see table 1). Then they used transmission models of HIV, TB, and malaria to estimate the additional impact on health that could be caused in different settings, either by COVID-19 interventions limiting routine programme activities, or due to COVID-19 cases overburdening the health system (table 2, figure 2).

Overall, the findings suggest that the impact of the pandemic varies according to the extent to which interventions against COVID-19 cause long disruptions to activities, and how successfully those measures reduce transmission of SARS-CoV-2, and avoid the health system being overwhelmed.

The greatest impact on HIV is projected to be from interruption to the supply and administering of ART, which may occur during times of high health system demand. In the worst case scenario, assuming no action or suppression-lift, countries with high rates of HIV typical in parts of southern Africa (20% prevalence among 15-49 year olds in 2018), could see up to 10% more deaths due to HIV over the next 5 years than would occur without COVID disruptions—equivalent to 612 additional HIV deaths per million population in 2020-2024. The researchers suggest that offering individuals receiving ART multi-month prescriptions or home delivery could ensure they can access treatment even in periods of highest health system demand.

For TB, the greatest impact is predicted to be from reductions in timely diagnosis and treatment of new cases, which could result from long periods of COVID-19 containment measures limiting access to services. In the worst case scenario, assuming suppression in countries with a very high burden typical in southern Africa (520 new cases per 100,000 population in 2018), TB deaths could rise by as much as 20% over the next 5 years (equivalent to 987 additional TB deaths per million population in 2020-2024) compared with when services are functioning normally.

The model predicts that the greatest impact on malaria burden could result from interruption of planned net campaigns, which usually take place every 3 years. In the worst case, with COVID-19 disruptions coinciding with the malaria transmission season and planned LLIN distribution, malaria deaths could increase by 36% over the next 5 years—equivalent to 474 additional malaria deaths per million population in 2020-2024.

“Many of the gains made in malaria control over the past decade have been due to distribution of long-lasting insecticide-treated nets in sub-Saharan Africa where the vast majority of malaria deaths occur. However, the COVID-19 pandemic will likely disrupt these distributions in 2020, resulting in more malaria deaths”, says co-lead author Dr Alexandra Hogan from Imperial College London, UK. “Routine preventative measures must be prioritised, ensuring mosquito net distribution campaigns and prophylactic treatments, such as mass drug distribution and seasonal malaria chemoprevention, are maintained.” [1]

The authors note several limitations, including that the scenarios modelled are not exhaustive but reflect the trade-offs between disruption due to COVID-19 interventions and periods of high health system demand. They also note that did not consider how long-term global changes such as a global recession might affect disease programmes.

Pragati Nagpal is a fashion designer by profession and has her own home-grown brand Mastaani that largely creates Indo-western and Indian ethnic wear. She has a very exclusive clientele that swears by her creativity and aesthetics. This kitty party queen of Delhi has made her own kitty party group with the crème de la crème of Delhi, making it one of the most coveted affairs in town.

The queen of Dilli Darlings Pragati Pankaj Nagpal is a fashion designer with the most amazing fashion sense. She is every bride’s dream to get ready from and throw her magic.

‘Dilli Darlings’ is a well-heeled, well-connected socialite of Delhi, intensely passionate, unapologetically real, effortlessly stylish and has the swag to set trends in one of India’s most vibrant cities. While some were born in the lap of luxury, others have earned their share of fame with victories at beauty pageants, their flair for networking, success in their respective careers, perseverance and their knack for attracting attention, adulation and applause from every quarter.

Her first tv debut was On Zee Tv, Dilli Darlings. Her first music album was a wedding song- a wedding wala song.

Her first bolly debut Vellapanti produced by Chandan Bakshi is coming very soon. And many more awaiting projects. Special Thanks to Pradeep Solanki.

Born and brought up in Delhi, she’s lived in Bombay throughout her career, have been a model/actor for TV Commercials and Print campaigns for Wills Lifestyle, Honda City, Airtel, Microsoft, Kodak, Calvin Clien, Colgate, Hit Mosquito Repellent, Haywards, Ayur Herbals, TCL, Sanskriti, Health total and the list goes on, done almost 22 music videos, has been on the super hit chartbuster with Diljit Dojansh, expected soon to be seen in another sizzling video produced by Pradeep Solanki, along with Tamil movies, comparing for International sports and more to it.
After being in the limelight for over years, Recently won the Mrs. India Universe QQ 2020.
Awaited is her upcoming Web series, music videos, print campaigns, sports, and much more.
She is anti-social and yet survived in the glamour industry for years, her Hardwork and passion seems to pay off, she is a Perfect Example of “Nothing is Impossible”.

Mohammad Shariq is active for many years in Prayagraj as a heavyweight leader. He is famous as Shariq Samajvadi and all of this publicity is because of his love for Mr.Akhilesh Yadav and Samajwadi Party.

He was born in a middle-class family and his whole family has been devoted to the service of society for ages. His predecessors have donated a huge amount of land for the Education and Industrial sectors. They also donated many acres of land for the financially backward families. And right now on that land, more than 2000 families are living rent-free.

He has raised his voice against many social impractical like caste discrimination, dowry, Untouchability, and many more. He has also helped various poor students to get the education they deserved and has helped more than 200 women by organizing schemes like group marriage. For the betterment of the environment, he has planted more than 100 trees every year. In the recent outbreak of Corona, he has helped many families by providing them Ration and Groceries required.

He has been an integral part of the Samajwadi Party for many years. He joined the party in 2010 and since then he has raised his voice against many injustices of society by organizing various strikes, memorandum, and Effigy Blowing to show his anger. He has performed every responsibility given to him by Mr.Akhilesh Yadav efficiently and in 2012 due to his commendable works Haji Parvez Ahmed Tanki emerged victorious from the city southern assembly with victory over the organization at 8 Sector 48 booths in Prayagraj city and in 2017 Ujjwal Raman Singh won from Karchana and in 2018 Nagendra Singh Patel won in Phulpur Lok Sabha elections. He worked as the in-charge of Vidhan Sabha Phulpur and Campierganj in the election year 2019, but this time he suffered a failure.

Being a Producer is like having skills such as leading a creative team, collaboration, employing appropriate interpersonal communication skills, and many more. Mr. Oshan Raj thought that he posses all the qualities of a producer and decided to take it as his profession. Other than being a music producer he also is an owner of ” GORDON ENTERTAINMENT”

When asked about his career he said “ I started my career in 2012 when I was just 18 and were having a dream of being a producer is just like someone exploring the planet Mars. It was hard as no one was there to support me in this time only my parents pushed me to walk on the path we wanted to walk. Only a few friends who were there to help me, others thought it as a mere joke. Oshan Raj released 60 Songs as a project manager and 21 songs as a producer. It is like his roaring towards his demotivators that oshan made it through with his passions.”

He already signed top Singers of Punjab including Jass Manak, Guri, Karan Randhawa, Hardy Sandhu, and many more well-known artists. He said-“working with them will help in increasing my experience along with my contacts. Working with them gives me exposure to new ideas about my producing techniques as well as my there thinking capabilities about his style of handling stuff.

While producers are generally looked upon as moneybags as far as the process of music-making is concerned, Oshan Raj has changed the rules completely. With that, he has also changed the image of a Punjabi music producer. Suave and well-read Oshan’s contribution to regional music totally beyond the common perception.

Nishant Agarwal is one of the youngest Entrepreneurs from Odisha. Breaking the stereotypes, he decided to start his entrepreneurial journey in the area of his passion and interests. Having an interest in various fields like Photography and Painting, he decided to make a business career in both of these and he is quite successful at it. Nishant is currently pursuing BBA in distance from Jain University Bangalore while running his business marathon. 

Entrepreneurship is a tough game to play. 

Nishant was passionate about making money and living life on his own terms is his motto which inspired this young man to start his venture. He saw that whenever he earns money by working on his passion, he feels accomplished. So, that was the motivating factor for him and very soon he decided that he will become an entrepreneur but having an interest in different fields, he was not very sure what he truly wants to do. He is a great photographer and artist. So, he decided to make a career in both of these fields but he was misunderstood by the people around him who thought that it won’t be wise to dedicate too much efforts in various fields at the same time but Nishant’s sheer hard work and dedication proved them wrong and he broke all the stereotypes. An Entrepreneur and An Artist. 

Finding his inspiration in Ritesh Aggarwal, he wishes to become like him but in his own field and his own way. For those unversed, Ritesh Aggarwal is the Founder, CEO of OYO Rooms, now a global brand and he is one of the youngest billionaires in the world and both Nishant and Ritesh shares the same state i.e. Odisha. On asking about his education and studies, he laughingly says that “Most people think that dropping out is one of the essential parts of becoming an entrepreneur but it is so wrong and I think that formal education is really important and an important part of one’s life.” 

The Ambitions Of This Creative Genius 

Nishant says that as of now, his artworks are being sold for lakhs of rupees and he is also making good money by his photography skills. He wishes to continue and is searching for his masterpiece. An artist’s true achievement is his masterpiece just like an entrepreneur’s real achievement is to make people’s life a little better than before and that is what Nishant seems to have understood and has been imbibing honestly with dedication. We wish all the best to this gentleman and hope that he gets all the riches that he wishes to achieve. 

Mylan has announced that the Drug Controller General of India (DCGI) has approved its remdesivir 100 mg/vial for restricted emergency use in India as part of the DCGI’s accelerated approval process to address urgent, unmet needs amid the evolving coronavirus 2019 (COVID-19) pandemic.

The drug is approved for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease. The drug will be launched under the brand name DESREMTM in India and will be available to patients in July at a price of INR 4,800, which is more than 80% less than the price at which the branded version of this product will be available to governments in the developed world, a statement issued by Mylan said.  

Mylan will manufacture remdesivir in India at its world-class injectables facilities, which also make product for the U.S. and have been inspected by the U.S. Food and Drug Administration (FDA) for compliance with good manufacturing practices. The company continues to work extensively toward expanding emergency use access for patients in the 127 low- and middle-income countries where it is licensed by Gilead

Mylan President Rajiv Malik said: “Mylan and Gilead Sciences have partnered for many years to make high quality medicines available to people who need them and have made significant progress to reduce the incidence of infectious diseases, including HIV/AIDS, around the world. We commend Gilead for their continued leadership on this front, and also applaud and are proud to continue partnering with the DCGI for its ongoing efforts to accelerate access to critical medicine for patients with COVID-19 in India.’’

Rakesh Bamzai, President, India and Emerging Markets, said: “The growing global threat of COVID-19 requires a commitment to action by everyone involved in public health. Mylan is cognizant of its responsibility in fighting this pandemic and will leverage its global resources and capabilities including R&D, regulatory, manufacturing and supply chain, while engaging with key stakeholders across the licensed territories to serve the patients in need and further its mission of creating better health for a better world.”

In a major move, pharmaceutical corporation Johnson & Johnson (J&J) has announced a reduction in the price of the tuberculosis (TB) drug bedaquiline. This should allow more people with drug-resistant forms of TB (DR-TB) to access this lifesaving drug. But the price should come down further and be extended to more countries, Médecins Sans Frontières/Doctors Without Borders (MSF) has said.  The price has been dropped by US$ 1.50 per day. 

MSF has been pressuring J&J on the price of the drug since it came to market in 2012, and launched a global campaign alongside people with TB and civil society last year, urging J&J to cut by more than half the price it charges for the drug in low- and some middle-income countries to $1/day. 

The World Health Organization (WHO) recommends the oral drug bedaquiline as the backbone of DR-TB treatment, to replace older, more toxic drugs that have to be injected daily and can cause intolerable side effects, such as deafness. In light of the COVID-19 pandemic, WHO has further advised countries to treat people with DR-TB in the safety of their homes by using all-oral regimens including bedaquiline instead of injections that require people to go to clinics. The older, longer DR-TB treatment used by many countries up to now required people to take up to 14,000 pills over the course of nearly two years, and to endure up to eight months painful daily injections.

“As the world reels from the COVID-19 pandemic, access to affordable treatment with bedaquiline is the need of the hour for people with DR-TB,” said Dr Pilar Ustero, TB Advisor at MSF’s Access Campaign. “Not only are the older drugs that have to be injected painful and can cause severe side effects, they also require people to travel to health facilities every day, putting them at increased risk of COVID-19 infection. With a reduced price, governments must urgently scale-up the use of bedaquiline as a core part of all-oral DR-TB regimens. Let’s not waste a minute putting an end to the suffering of people with DR-TB.”

The price charged by J&J for bedaquiline has remained a critical barrier to countries scaling up this lifesaving treatment, especially considering bedaquiline is just one of multiple drugs required in a DR-TB treatment regimen. Given the substantial taxpayer funding J&J received for this drug’s research and development from the United States (US) and other countries, MSF and others have been calling for the corporation to lower the price to increase people’s access. A study conducted by researchers at Liverpool University showed that bedaquiline could be produced and sold at profit for as little as $0.25 per day.

“J&J didn’t develop this drug alone,” said Sharonann Lynch, Senior HIV & TB Advisor for MSF’s Access Campaign. “Bedaquiline was developed with considerable taxpayer, non-profit and philanthropic support – J&J received public investments in the hundreds of millions of dollars, including grants from the US government and various financial incentives,and treatment providers like MSF contributed to the research on the drug. J&J should not be charging high prices for this drug anywhere.”

The newly reduced price is 32% lower than the previous lowest price, available to a list of countries determined by J&J, and tied to purchase commitments made through the Global Drug Facility (GDF),an organisation run by the Stop TB Partnership that supplies TB drugs to low- and middle-income countries. Countries who do not purchase from GDF are not eligible for the lower price and continue to face higher prices charged by J&J, or from its Russian commercial partner Pharmstandard for some countries in the Commonwealth of Independent States. For example, the Russian Federation pays over $8 per day for bedaquiline, which is significantly higher than the price available now to countries eligible for the reduced price of $1.50 per day.  

MSF called on J&J to further reduce the price and offer the lower price to all countries with a high DR-TB burden, so that more lives can be saved.

J&J is currently the sole manufacturer of bedaquiline and has patented the drug in most countries, controlling the price at which it is sold. J&J’s monopoly blocks other manufacturers in India and elsewhere from producing and supplying more affordable generic versions. While the corporation’s patent on the base compound of bedaquiline expires in 2023, it has resorted to ‘patent ever-greening’ by filing additional patentsto extend its patent monopoly on the drug to 2027 in many TB affected countries. Generic manufacturers say they are able to produce more affordable versions starting in 2021, but are blocked from entering the market by J&J’s patent. MSF has been calling on J&J not to enforce its patents on bedaquiline and cease its efforts to prolong its monopoly through patent extensions that would further delay the availability of quality-assured generic versions of the drug.